Table 1. Relapse-free survival and overall survival after blinatumomab retreatment.

Pt	Agea	Study	Initial treatment			Intervening alloHSCT	Retreatment			Subsequent systemic therapy	RFS (months)	Overall survival (months)
			Daily dose	Response duration (months)	Blasts at relapse		Daily dose	Grade ⩾3 neurologic event	Best hematologic response
1	12	205	15–30 μg/m2	12.4	—		5–15 μg/m2		PD			0.7b
2	4		5–15 μg/m2	3.4	93%	Yes	5–15 μg/m2		No response	Yes		6.7
3	77	206	15 μg/m2	7.8	10%		15 μg/m2	Yes	PR			12.9
4c	38		5–15–30 μg/m2	17.5	10%		5–15–30 μg/m2		CR		8.6
					32%		5–15–30 μg/m2		CR	Yes	9.7	20.0b
5	24		5–15 μg/m2	7.6	—	Yes	5–15 μg/m2		Hypocellular			9.4
6	62		15 μg/m2	d	—	Yes	15 μg/m2		CRh		3.9	4.8
7	21		5–15 μg/m2	10.6	10%		5–15 μg/m2	Yes	—			12.3
8	20	211	9–28 μg	14.2	—		9–28 μg	Yes	CR	Yes	1.7	3.7b
9	29		9–28 μg	10.5	—	Yes	9–28 μg		PD			0.7
10	26		9–28 μg	5.1	—	Yes	9–28 μg		PD			1.8
11	25		9–28 μg	11.3	—	Yes	9–28 μg		CRh		3.7	4.6b
										Median (95% CI)	3.8 (1.7, 8.6)	9.4 (0.7, 12.9)

Abbreviations: —, not assessed; alloHSCT, allogeneic hematopoietic stem cell transplantation; CI, confidence interval; CR, complete remission; CRh, CR with partial hematologic recovery; PD, progressive disease; PR, partial remission; RFS, relapse-free survival.

^aAge, in years, before initial treatment.

^bCensored observation (ongoing survival).

^cThis patient received blinatumomab retreatment twice.

^dDuration of response was not calculated for this patient because the initial response occurred after blinatumomab treatment ended.